Login
Related Links
Gene Therapy Research Institutes - Europe
- Finland - A.I. Virtanen Institute of Molecular Medicine, University of Kuopio
- Finland - Cancer Gene Therapy Group, University of Helsinki
- Israel - The Goldyne Savad Institiute of Gene Therapy, Hadassah, Jerusalem
- Italy - San Raffaele Telethon Institute for Gene Therapy (HSR-TIGET), Milan
- Italy - TIGEM - Telethon Institute of Genetics and Medicine, Napoli
- Netherlands - Oncogenomics VUmc, Amsterdam
- Netherlands - Pharmaceutical Gene Modulation, Groningen
- Spain - Viral Vector Production Unit (UPV), Universitat Autonoma de Barcelona
- Sweden - Molecular Medicine and Gene Therapy, Lund University
- Turkey - Human Gene and Cell Therapy Center, Akdeniz University Hospitals and Clinics
The research is on cardiovascular, neurodegenerative, and metabolism-related diseases. Main target genes are vascular growth factors, and LDL receptor in cardiovascular area and cytotoxic genes in cancer therapy.
The group of Akseli Hemminki uses gene therapy and oncolytic viruses to improve the treatment of cancers lacking currently available effective modalities.
Research covers a wide range of diseases along three main tracks: cellular gene therapy, viral vectors and non-viral vectors. The Institute is headed by Prof. Eithan Galun, M.D.
The group headed by Luigi Naldini performs basic research on gene transfer technologies and new gene therapy strategies for immunodeficiencies, lysosomal storage disorders, thalassemia, hemofilia B.
The interest of group of Alberto Auricchio is to use Adeno-Associated Virus (AAV)-mediated gene transfer as potential therapy for ocular and metabolic diseases
The Gene Therapy research group aims to design new anti-cancer therapies using oncolytic adenoviruses and modulation of gene expression, with particular attention to the p53 tumor suppressor pathway.
The department is headed by Prof. Hidde Haisma and is focused on the development of drugs for the therapeutic manipulation of gene activity. The research is focused on cancer and inflammatory diseases.
UPV is a vector core specialized in the cloning, production and purification of adenovirus (human and canine) and adeno-associated virus (AAV) serotypes for public institutions and private companies all over the world.
The laboratory investigates the properties of blood stem cells and is developing cell and gene therapy for blood disorders: Diamond-Blackfan Anemia and Gaucher Disease.
The laboratory is headed by Prof. Dr. Salih Sanlioglu and his team are involved in the development of novel gene therapy methods for patients with type 2 diabetes using lentiviral vectors.
Info Research Centers
Overview of research institutes, centers and universities involved in pre-clinical and clinical gene therapy research:
Check here also the European Union Framework Programme Six (FP6) Integrated Projects, such as Attack, Clinigene, Consert and GIANT.
See also the European Union Framework Programme Seven (FP7) Integrated Projects.
Your Research Institute not listed? Click here to suggest
Like to work for a research center? Find here the perfect job in gene therapy.
 |
US & Canada |
|
Europe |
|
Australia |
Check here also the European Union Framework Programme Six (FP6) Integrated Projects, such as Attack, Clinigene, Consert and GIANT.
See also the European Union Framework Programme Seven (FP7) Integrated Projects.
Your Research Institute not listed? Click here to suggest
Like to work for a research center? Find here the perfect job in gene therapy.
Gene Therapy News
- AaviGen, SK pharmteco Announce Manufacturing Agreement for Heart Failure Gene Therapy - BioPharm International
Sat, 12 Oct 2024 17:37:1 GMT - HNSA-5487 Significantly Reduces IgG Levels, FDA Removes Hold on AOC 1001, DMD Gene Therapy Shows No Impact on Cardiac Outcomes - Neurology Live
Sat, 12 Oct 2024 13:09:1 GMT - Gene therapy benefits boys with rare brain disease, but hematologic cancer remains a risk - Healio
Fri, 11 Oct 2024 17:30:2 GMT - Fierce Pharma Asia—AstraZeneca-CSPC heart med deal; Astellas' gene therapy pact, new cell therapy site - FiercePharma
Fri, 11 Oct 2024 15:48:5 GMT - Worries Mount Over Cancer Risks in Bluebird Bio's Gene Therapy - Benzinga
Fri, 11 Oct 2024 15:09:1 GMT - Buy, Sell, Hold: Cell and Gene Therapy - Pharmaceutical Technology Magazine
Fri, 11 Oct 2024 13:01:3 GMT - Magnetically regulated gene therapy tech offers precise brain-circuit control - Medical Xpress
Thu, 10 Oct 2024 20:25:0 GMT - Hubble Therapeutics Taps Andelyn to Manufacture Clinical Grade AAV for Eye Disorder Gene Therapy - Genetic Engineering & Biotechnology News
Thu, 10 Oct 2024 19:29:0 GMT - Bluebird bio’s Skysona led to seven cases of blood cancer in gene therapy trials - Yahoo Finance
Thu, 10 Oct 2024 19:22:1 GMT - Bluebird bio’s Skysona led to seven cases of blood cancer in gene therapy trials - Pharmaceutical Technology
Thu, 10 Oct 2024 18:24:3 GMT - Report gives update on boys with rare brain disease 6 years after gene therapy - UPI News
Thu, 10 Oct 2024 16:10:4 GMT - Sarepta’s gene therapy is fully approved, but its stock has tanked. Here’s why - STAT
Thu, 10 Oct 2024 16:02:5 GMT - Magnetically Regulated Gene Therapy Tech Offers Precise Brain-Circuit Control - Weill Cornell Medicine Newsroom
Thu, 10 Oct 2024 15:33:5 GMT - 7 Children Receiving Bluebird’s Gene Therapy Developed Blood Cancers: Study - BioSpace
Thu, 10 Oct 2024 15:18:5 GMT - Highly targeted approach supports ALS gene therapy development - ALS News Today
Thu, 10 Oct 2024 15:14:0 GMT